Results 51 to 60 of about 292,142 (337)

Treatment retention in opioid agonist therapy: comparison of methadone versus buprenorphine/naloxone by analysis of daily-witnessed dispensed medication in a Canadian Province

BMC Psychiatry, 2022
Background The last decade has shown a remarkable increase in the rates of illicit opioid use in Canada and internationally, which is associated with large increases in opioid related morbidity and mortality.
Joseph Sadek, Joseph Saunders
doaj   +1 more source

Evaluation of the analgesic effect of 4-anilidopiperidine scaffold containing ureas and carbamates [PDF]

, 2016
Fentanyl is a powerful opiate analgesic typically used for the treatment of severe and chronic pain, but its prescription is strongly limited by the well-documented side-effects.
Benyhe, Sa ́ndor, CARRADORI, Simone, Csaba To ̈mbo ̈ly, Erdei, Anna I., Ferenc O. ̈tvos, Ferenc Za ́dor, Fidanza, Lorenzo, Marzoli, Francesca, Mirzaie, Sako, MOLLICA, Adriano, MONTI, LUDOVICA, Moriello, Aniello Schiano, Novellino, Ettore, Petrocellis, Luciano De, PIERETTI, stefano, Samavati, Reza, STEFANUCCI, AZZURRA, Szabolcs Dvora ́csko, Szucs, Edina   +18 more
core   +1 more source

The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study.

Addiction, 2021
BACKGROUND AND AIMS There is limited evidence on the relationship between retention in opioid agonist treatment for opioid dependence and characteristics of treatment prescribers.
C. Bharat, S. Larney, S. Barbieri, T. Dobbins, Nicola R. Jones, M. Hickman, N. Gisev, R. Ali, L. Degenhardt   +8 more
semanticscholar   +1 more source

State criminal justice policy context and opioid agonist treatment delivery among opioid treatment admissions, 2015 [PDF]

Drug and Alcohol Dependence, 2020
Criminal justice referral to treatment is associated with reduced odds of receiving opioid agonist treatment (OAT), the gold-standard treatment for opioid use disorder. States vary substantially in the extent of criminal justice system involvement in opioid treatment; however, the effects on treatment provision are not clear.
Shivani Mantha, Pia M. Mauro, Christine M. Mauro, Silvia S. Martins   +3 more
openaire   +2 more sources

Modeling the population‐level impact of opioid agonist treatment on mortality among people accessing treatment between 2001 and 2020 in New South Wales, Australia

Addiction, 2021
Background and Aims The individual‐level effectiveness of opioid agonist treatment (OAT) in reducing mortality is well established, but there is less evidence on population‐level benefits. We use modeling informed with linked data from the OAT program in
A. Chaillon, C. Bharat, J. Stone, Nicola R. Jones, L. Degenhardt, S. Larney, Michael Farrell, P. Vickerman, M. Hickman, N. Martin, A. Bórquez   +10 more
semanticscholar   +1 more source

Postoperative opioid misuse in patients with opioid use disorders maintained on opioid agonist treatment

Journal of Substance Abuse Treatment, 2020
Patients recovering from opioid use disorders (OUD) may be prone to relapse and opioid misuse in the postoperative period due to re-exposure to prescription opioids for pain control. This retrospective study analyzed the incidence of confirmed opioid misuse in the postoperative period in patients with OUDs enrolled in an opioid agonist treatment (OAT ...
Khodadad, Namiranian, Jonathan, Siglin, John David, Sorkin, Edward J, Norris, Minu, Aghevli, Edward C, Covington   +5 more
openaire   +3 more sources

Impact of opioid agonist treatment on mental health in patients with opioid use disorder: a systematic review and network meta-analysis of randomized clinical trials

The American Journal of Drug and Alcohol Abuse, 2021
Background: There is a knowledge gap in systematic reviews on the impact of opioid agonist treatments on mental health. Objectives: We compared mental health outcomes between different opioid agonist treatments and placebo/waitlist, and between the ...
E. Moazen-Zadeh, Kimia Ziafat, Kiana Yazdani, M. Kamel, J. Wong, A. Modabbernia, P. Blanken, U. Verthein, C. Schütz, K. Jang, S. Akhondzadeh, R. M. Krausz   +11 more
semanticscholar   +1 more source

Suboxone: History, controversy, and open questions

Frontiers in Psychiatry, 2022
There are more than 200 opioid overdose deaths each day in the US. In combating this epidemic we look to available treatment tools. Here, we find only three medications approved by the Food and Drug Administration (FDA) for the treatment of opioid use ...
Andy Sivils, Paige Lyell, John Q. Wang, Xiang-Ping Chu   +3 more
doaj   +1 more source

Dopamine-D1 and δ-opioid receptors co-exist in rat striatal neurons [PDF]

, 2006
Cocaine’s enhancement of dopaminergic neurotransmission in the mesolimbic pathway plays a critical role in the initial reinforcing properties of this drug. However, other neurotransmitter systems are also integral to the addiction process.
Ambrose-Lanci, L. M., Gallagher, S. M., Unterwald, E. M., Van Bockstaele, E. J.   +3 more
core   +2 more sources

Synthesis, biological evaluation, and SAR studies of 14β-phenylacetyl substituted 17-cyclopropylmethyl-7, 8-dihydronoroxymorphinones derivatives : Ligands with mixed NOP and opioid receptor profile [PDF]

, 2018
© 2018 Kumar, Polgar, Cami-Kobeci, Thomas, Khroyan, Toll and Husbands.A series of 14β-acyl substituted 17-cyclopropylmethyl-7,8-dihydronoroxymorphinone compounds has been synthesized and evaluated for affinity and efficacy for mu (MOP), kappa (KOP), and ...
Cami-Kobeci, Champion, Cheng, Christoph, Ding, Dooley, Greedy, Greiner, Gumusel, Günther, Hu, Huang, Jenck, Khroyan, Khroyan, Kiguchi, Ko, Lewis, Lewis, Lia, Manabe, Meunier, Meunier, Mogil, Mollereau, Moynihan, Pomonis, Raffa, Reinsceid, Rizzi, Rossi, Saccone, Sandin, Schmidhammer, Schmidhammer, Schmidhammer, Spagnolo, Sukhtankar, Thompson, Toll, Toll, Traynor, Ueda, Vanderah, Váradi, Woodcock, Yu, Zeilhofer   +47 more
core   +4 more sources